NCT04504253View on ClinicalTrials.gov

A Pilot Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 3, 2020

Primary Completion Date

August 2, 2023

Study Completion Date

August 2, 2023

Conditions
Major Depressive Disorder
Interventions
DIETARY_SUPPLEMENT

Creatine monohydrate

Creatine monohydrate loose powder

DRUG

Placebo

Placebo control (dextrose 5mg) matched to creatine monohydrate loose powder

Trial Locations (1)

84108

University of Utah Department of Psychiatry, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT04504253 - A Pilot Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder | Biotech Hunter | Biotech Hunter